Literature DB >> 21472012

An evidence-based systematic review on medical therapies for inflammatory bowel disease.

Nicholas J Talley1, Maria T Abreu, Jean-Paul Achkar, Charles N Bernstein, Marla C Dubinsky, Stephen B Hanauer, Sunanda V Kane, William J Sandborn, Thomas A Ullman, Paul Moayyedi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21472012     DOI： 10.1038/ajg.2011.58

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  78 in total

Review 1.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

Review 3.  Surgical treatment of ulcerative colitis in the biologic therapy era.

Authors:  Alberto Biondi; Marco Zoccali; Stefano Costa; Albert Troci; Ettore Contessini-Avesani; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

4.  A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease.

Authors:  J Claire Wilson; Raoul I Furlano; Susan S Jick; Christoph R Meier
Journal:  J Gastroenterol       Date:  2016-04-07       Impact factor: 7.527

5.  Indian Society of Gastroenterology consensus statements on Crohn's disease in India.

Authors:  Balakrishnan S Ramakrishna; Govind K Makharia; Vineet Ahuja; Uday C Ghoshal; Venkataraman Jayanthi; Benjamin Perakath; Philip Abraham; Deepak K Bhasin; Shobna J Bhatia; Gourdas Choudhuri; Sunil Dadhich; Devendra Desai; Bhaba Dev Goswami; Sanjeev K Issar; Ajay K Jain; Rakesh Kochhar; Goundappa Loganathan; Sri Prakash Misra; C Ganesh Pai; Sujoy Pal; Mathew Philip; Anna Pulimood; Amarender S Puri; Gautam Ray; Shivaram P Singh; Ajit Sood; Venkatraman Subramanian
Journal:  Indian J Gastroenterol       Date:  2015-03-14

6.  Improving IBD Care: A Personalized Approach to Management.

Authors:  Stephen B Hanauer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

Review 7.  A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics.

Authors:  L Vitetta; D Briskey; E Hayes; C Shing; J Peake
Journal:  Inflammopharmacology       Date:  2012-03-18       Impact factor: 4.473

Review 8.  Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Authors:  Kavinderjit S Nanda; Adam S Cheifetz; Alan C Moss
Journal:  Am J Gastroenterol       Date:  2012-11-13       Impact factor: 10.864

Review 9.  Crucial steps in the natural history of inflammatory bowel disease.

Authors:  Giovanni Latella; Claudio Papi
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 10.  When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.

Authors:  Suneeta Krishnareddy; Arun Swaminath
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.